Optimizing Care For the Management of Benign Prostatic Hyperplasia
Premiere Date: Monday, June 30, 2014This activity offers CE credit for:
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Tuesday, June 30, 2015
Note: Credit Is No Longer Available
 | Kevin T. McVary, MD, FACS Professor and Chair Division of Urology/Department of Surgery Southern Illinois University School of Medicine Springfield, IL |
 | Culley C. Carson, III, MD, FACS Rhodes Distinguished Professor of Urology University of North Carolina Chapel Hill, NC |
 | Steven A. Kaplan, MD E. Darracott Vaughan Jr. Professor of Urology Chief, Institute for Bladder and Prostate Health Weill Cornell Medical College Director, Iris Cantor Men's Health Center New York Presbyterian Hospital, Weill Cornell Medical Center New York, NY |
 | David R. Staskin, MD Associate Professor of Urology Tufts University School of Medicine Steward Health-St. Elizabeth's Medical Center Boston, MA |
Prostate enlargement, or benign prostatic hyperplasia (BPH), is an important men’s health condition. Over eight million men (above the age of 50) in the United States alone are undergoing treatment for BPH, but many more have the condition. BPH shows increasing incidence and prevalence with age, affecting over half of men over age 60, and 90% of those over age 85.1
BPH—characterized by myriad lower urinary tract symptoms including urinary hesitancy, frequency, and nocturnal diuresis, as a well as associated erectile dysfunction—impacts men’s health status and quality of life. Given its associated prevalence, morbidity, health care costs, and changing face of management, BPH is undermanaged in the health care setting.2
In this interactive Case Challenge Workshop, faculty will engage participants in collaborative discussion of the data using audience response technology, patient case vignettes, and mini-breakout sessions—which present a unique chance for direct access to experts with a low faculty to attendee ratio. Each mini-breakout session is led by expert faculty is designed to identify challenges, share insights, and problem-solve to improve the care of patients with BPH and its comorbidities.
- American Urological Association [AUA]. American Urological Association Guideline: Management of Benign Prostatic Hyperplasia (BPH). AUA Website. http://www.auanet.org/content/clinical-practice-guidelines/clinical-guidelines/main-reports/bph-management/authors.pdf. Revised 2010. Accessed January 29, 2014.
- Donnell RF. Benign prostate hyperplasia: a review of the year's progress from bench to clinic. Curr Opin Urol. 2011;21(1):22-26. PMID: 21171199.
This educational activity centers on the CMEO Make One Change Statement. This statement is crafted from pertinent quality measures or clinical guidelines as a performance challenge to all participants. We work with faculty to determine one change that can be implemented in clinical practice that would result in improved care of patients. The Make One Change for this activity should focus on this performance challenge:
Use established, guidelines-based, measurement tools with all patients with BPH/LUTS to monitor symptoms, treatment response, and quality of life.
At the end of this CE activity, participants should be able to:
- Describe the pathophysiology and clinical presentation of BPH/LUTS and common comorbidities.
- Implement a treatment plan for patients with BPH/LUTS that considers all available, approved, evidence-based, pharmacological options and nonpharmacological interventions.
- Apply measurement-based care in the management plan to monitor symptoms, treatment response, and impact of BPH/LUTS on quality of life.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Review the typical clinical presentation of BPH/LUTS.
- Describe a treatment plan that includes evidence-based pharmacological options, and nonpharmacological interventions.
- Discuss ways to address quality of life in patients with BPH/LUTS.
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
CME Credit (Physicians):
CME Outfitters, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CME Outfitters designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
CNE Credit (Nurses): Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.25 contact hours
Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1.25 contact hours of pharmacotherapeutic contact hours.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.25 contact hours (0.125 CEUs)
Universal Activity Number: 0376-0000-14-005-H01-P
Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST903 (requires free account activation), and participants can print their certificate or statement of credit immediately (80% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. McVary has disclosed that he has received research support from Allergan Inc.; Lilly and Company/ICOS Corporation; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); and NeoTract, Inc. He is on the speakers bureau of GlaxoSmithKline. He serves as a consultant for Allergan Inc.; Lilly and Company/ICOS Corporation; NeoTract, Inc.; NxThera, Inc.; and Watson Pharmaceuticals, Inc.
Dr. Carson has disclosed that he has received grant and research support from Auxilium Pharmaceuticals, Inc. He serves on the speakers bureaus of American Medical Systems, Inc. (AMS); Auxilium Pharmaceuticals, Inc.; Eli Lilly and Company; and GlaxoSmithKline. Dr. Carson serves as a consultant for American Medical Systems, Inc. (AMS) and Auxilium Pharmaceuticals, Inc.
Dr. Kaplan has no disclosures to report.
Dr. Staskin has disclosed that he serves on the speakers bureau for Allergan Inc. and Astellas Pharma US, Inc. He is a consultant for Allergan, Inc.; AltheRX Pharmaceuticals; Astellas Pharma US, Inc.; and Endo-American Medical Systems, Inc. He received royalties from America Medical Systems, Inc.
Disclosures were obtained from the CME Outfitters, LLC staff: Nothing to Disclose
John M. Rodgers, MD (peer reviewer) has no disclosures to report.
Robert Kennedy (planning committee) has no disclosures to report.
Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.
Sandra Haas Binford, MAEd (planning committee) has no disclosures to report.
Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
CME Outfitters, LLC, the faculty, and Lilly do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
MMV-053-063014-11
